Rocket Pharmaceuticals Soars 26.8% on FDA Trial Resumption

Rocket Pharmaceuticals' stock surged 26.8% in pre-market trading on August 20, 2025, marking a significant boost in investor confidence.

Rocket Pharmaceuticals' stock experienced a notable surge following the FDA's decision to lift a hold on the Phase 2 trial for RP-A501, a gene therapy aimed at treating Danon disease. This move has reinvigorated investor optimism, as the trial is set to resume with adjusted dosing protocols after earlier safety concerns had temporarily halted progress.

Analysts have provided a bullish outlook for Rocket Pharmaceuticals, with an average price target of $7.42, suggesting a potential upside of 155.09% from the current stock price. This optimistic projection is supported by a consensus recommendation of "Outperform" from 17 brokerage firms, indicating a favorable outlook from market analysts.